Legal Status Overview
RestrictedPeptides are restricted, not categorically banned, in California: the state has no statute that singles out "peptides" or "research chemicals" as their own legal category, so their legality depends entirely on federal drug-approval and compounding law layered under California's general pharmacy and drug statutes. California Board of Pharmacy compounding rules and the Sherman Food, Drug, and Cosmetic Law require that any peptide given to a patient be either an FDA-approved drug prescribed by a licensed practitioner or a compound prepared by a state-licensed 503A/503B pharmacy using a bulk substance FDA has approved for compounding; most "research peptides" such as BPC-157 and TB-500 fail that test today. A 2025-2026 bill, AB 2442, would create a formal state research/investigational-access program for peptides but has not been enacted.
Key Points
- California has no statute or Board of Pharmacy regulation that defines "peptides" or "research chemicals" as a distinct legal category; the state instead relies on general pharmacy, compounding, and drug-approval law. [5]
- Under California's Sherman Food, Drug, and Cosmetic Law, administered by the State Department of Public Health, it is unlawful to sell, deliver, or give away any new drug that lacks FDA approval, which covers unapproved research peptides sold for human use. [11]
- The California State Board of Pharmacy licenses and inspects compounding pharmacies, which must comply with both state sterile-compounding rules and the federal 503A/503B framework before preparing any peptide for a specific patient. [13]
- The Medical Board of California and the California Board of Pharmacy treat the administration of "research use only" peptides like BPC-157 to patients as unlicensed practice of medicine and distribution of an unapproved new drug, exposing clinics to license suspension, civil fines, and criminal prosecution. [3]
- A person cannot legally buy or import research-labeled peptides such as BPC-157 or TB-500 for personal human use in California, since the "not for human consumption" label does not create a legal safe harbor and such products remain unapproved new drugs under state and federal law. [7]
- Telehealth prescribing of peptides is legal in California when a clinician licensed by the Medical Board of California prescribes an FDA-approved peptide drug or a preparation a licensed pharmacy can lawfully compound under Section 503A. [6]
- As of 2026 the FDA has been actively revising its 503A bulks lists for peptides, including proposing public review of whether BPC-157, KPV, TB-500, MOTs-C, DSIP, Semax, and Epitalon should be added as lawfully compoundable, which directly determines whether California 503A pharmacies may compound them. [9]
- A California bill, AB 2442 (2025-2026 session), would create a California Investigational Peptide and Novel Compound Research and Therapeutic Access Program to allow state-authorized research and supervised investigational access to peptides, but it remains in committee and is not current law. [1]
Peptide-by-peptide status in California
| BPC-157 | BPC-157 is not legally compoundable or prescribable for human use in California because it lacks a USP monograph, is not a component of an FDA-approved drug, and is not currently on the FDA's Category 1 503A bulks list, leaving only unapproved "research use" sales that cannot lawfully be administered to patients. [10] |
|---|---|
| Semaglutide / tirzepatide (GLP-1 class) | Semaglutide is legal to prescribe in California as an FDA-approved drug, but compounded versions (including semaglutide salt forms like semaglutide sodium or acetate) are generally restricted to drug-shortage or allergy-based exceptions and salt forms are expressly prohibited by the FDA and California Board of Pharmacy. [4] |
| TB-500 | TB-500 is treated the same as other unapproved research peptides in California and is included among the compounds the FDA is currently reviewing for possible addition to the 503A bulks list, meaning it is not presently a lawful ingredient for patient-specific compounding or human use. [9] |
| Human growth hormone (HGH/somatropin) and sermorelin | FDA-approved somatropin (HGH) is legal in California only by prescription for approved indications, while sermorelin, a GHRH analog, is one of the few peptides with a recognized lawful 503A compounding pathway for licensed-pharmacy preparation. [6] |
Sources
Last researched: 2026-10-02
Frequently asked questions
Can I buy peptides in California without a prescription?
No, in California you cannot lawfully obtain peptides like BPC-157 or semaglutide for human use without a prescription from a licensed practitioner; research-labeled peptides bought online remain unapproved new drugs regardless of "not for human consumption" disclaimers. [7]
Is it legal to import or travel with research peptides into California?
No reliable California-specific source addresses personal importation of research peptides directly, but general state and federal drug law treats unapproved peptides intended for human use as unlawful regardless of how they entered the state, so bringing them in for personal injection carries legal risk.
Can a telehealth doctor legally prescribe peptides to me in California?
Yes, a clinician licensed by the Medical Board of California can legally prescribe an FDA-approved peptide drug or a compoundable preparation via telehealth after an appropriate clinical evaluation, but this does not extend to research-labeled peptides lacking an approved compounding pathway. [6]
What happens if a California clinic uses research peptides like BPC-157 on patients?
A California clinic administering research-grade peptides to patients risks license suspension by the Medical Board of California or Board of Pharmacy, civil fines, and criminal prosecution, because regulators classify this as unlicensed practice of medicine and distribution of an unapproved new drug. [3]
Is BPC-157 legal in California?
BPC-157 is not legal for human use in California because it has no FDA-approved drug status, no USP monograph, and is not on the FDA's approved 503A compounding bulks list, so it can only be sold as an unapproved research chemical, not administered to patients. [10]